Anyone had CAR-T treatment for Scleroderma or Lupus? Any other CAR-T?

CAR-T treatments for autoimmune diseases currently running in clinical trials are similar to already approved CAR-Ts for blood cancers, like B Cell Lymphoma, Multiple Myeloma and Acute Myeloid Leukemia.

Here is a link to Breyanzi CAR-T approved for multiple lymphoma indications. The website provides comprehensive information regarding what is involved in CAR-T treatment and potential toxicities. May be a good read for autoimmune disease as well.
https://www.breyanzi.com

Here is another CAR-T approved for Multiple Myeloma. Please see a link to CARVYKTI website.
CARVYKTI® (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma.

Read carefully Important Safety Information section - its safety profile is similar to CAR-Ts currently tested in clinical trial for autoimmune diseases.
https://www.carvyktihcp.com/

This is a clinical trial with BMS CAR-T for multiple autoimmune diseases which is ongoing and open to enrollment:
https://www.cartautoimmune.com/hcp/ssc
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1)

You can look up the details on clinicaltrial.gov:
https://clinicaltrials.gov/study/NCT05869955

I am posting information for a biotech company Kyverna, which is specializing in the developement of CAR-T therapies for autoimmune diseases:
https://kyvernatx.com/platform-pipeline/car-t-cell-therapy/
Their treatments are early on in the development, but it may be worth watching the progress.
https://kyvernatx.com/platform-pipeline/clinical-trials/
From Kyverna website: CAR T cells have the potential for therapeutic breakthrough in
B-cell driven autoimmune diseases.
Kyverna is the exclusive worldwide licensee of a next-generation CAR T construct targeting CD19 for use in the autologous, mivocabtagene autoleucel (miv-cel, KYV-101) and KYV-102, and allogeneic, KYV-201, cell therapies for B-cell driven autoimmune diseases.
The diseases that are included in the clinical program: RA, Lupus, Systemic Sclerosis, Multiple Sclerosis, Myasthenia Gravis, Stiff Person Syndrome.

https://www.novartis.com/clinicaltrials/study/nct06655896
A clinical trial from Novartis is now recruiting patients with diffuse systemic sclerosis. The design is randomized, CAR-T vs Rituximab.

All ongoing clinical trials are posted on http://www.clinicaltrials.gov website. Here is a link to a search under systemic sclerosis CAR-T for the study with Belimumab:
https://clinicaltrials.gov/study/NCT05878717
Belimumab is already approved in Lupus. Now it is being tried in systemic sclerosis.

Here is an article covering overview of a small number of patients treated with CAR-t therapy that have been followed for more than 15 months.

CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
https://www.nejm.org/doi/full/10.1056/NEJMoa2308917

@altabiznet Just wondering if you have an interest in CAR T trials for a specific reason.

@becsbuddy

One study/site is offering me to go for CAR-T therapy. It would be helpful to hear from the patients with real-life experience how they tolerated the procedure and whether there was a good durable response.

@becsbuddy Good morning..reason Becky is Systemic Lupus, Sjögren’s & type 2 Diabetes (under control AIC 6.1🎉 been taking Hydroxy like 10 years approx. moderate Arthritis everywhere..
I want to get better not worse 😢
I’m glad to meet you!
Thank you,
Wendy